Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Lung Cancer Drugs Market Forecast: What Value Will The Market Reach By 2030?
The lung cancer drugs market has experienced significant expansion over recent years. This market is projected to expand from $52.98 billion in 2025 to $58.23 billion in 2026, registering a compound annual growth rate (CAGR) of 9.9%. Key drivers for historical market expansion include elevated smoking prevalence, increasing rates of lung cancer, broad adoption of chemotherapy, the growth of oncology hospitals, and enhanced availability of generic cancer drugs.
The lung cancer drugs market size is anticipated to undergo significant growth over the next few years. It is projected to expand to $88.06 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.9%. This expansion throughout the forecast period is attributable to various factors, such as the development and increased use of targeted and immunotherapy drugs, higher rates of lung cancer screening, escalating healthcare expenditure in oncology, an aging global population, and the increasing approval of combination therapies. Key trends expected during this forecast period include the rising adoption of targeted lung cancer treatments, a greater reliance on combination drug regimens, an intensified focus on early-stage lung cancer management, the broadening of personalized treatment protocols, and an increase in the administration of oncology drugs within hospital settings.
Get A Free Sample Report With In-Depth Market Insights:
Lung Cancer Drugs Market Growth Catalysts And Demand Drivers
The rising incidence of lung cancer is projected to fuel expansion within the lung cancer drugs market in the coming years. This severe malignancy necessitates prompt and efficient therapeutic interventions, such as chemotherapy, targeted treatments, immunotherapies, and combined regimens, to enhance patient survival rates. The growth in lung cancer cases is largely attributed to environmental contaminants and carcinogen exposure, in addition to genetic factors, all of which contribute to mutations in lung cells, even among individuals who do not smoke. This escalating prevalence of lung cancer underpins the lung cancer drugs market by intensifying the demand for superior treatment options that can extend life expectancy, slow tumor advancement, and elevate patients’ overall quality of life. For example, in January 2023, the American Cancer Society, a US-based voluntary health organization focused on eradicating cancer, estimated approximately 238,340 new lung cancer cases (comprising 117,550 in men and 120,790 in women) and around 127,070 fatalities from lung cancer (with 67,160 in men and 59,910 in women) for 2023. Consequently, the growing rate of lung cancer prevalence is propelling the expansion of the lung cancer drugs market.
Lung Cancer Drugs Market Breakdown By Product Type And Application
The lung cancer drugs market covered in this report is segmented –
1) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs
2) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)
3) By End User: Hospitals, Clinics, Other End-Users
Lung Cancer Drugs Market Trends Shaping Long-Term Demand
Leading companies in the lung cancer drugs market are concentrating on product innovation and advanced formulations, such as chemotherapy-free combination therapies specifically targeting EGFR mutations. This strategic focus aims to boost treatment efficacy, decrease systemic toxicity, and improve the overall quality of life for individuals suffering from advanced non-small cell lung cancer (NSCLC). These therapies facilitate precision oncology approaches by offering targeted inhibition of specific molecular pathways that drive tumor growth. For instance, in August 2024, Johnson & Johnson, a US-based pharmaceutical company, obtained U.S. FDA approval for Rybrevant plus Lazcluze as a first-line, chemotherapy-free treatment for patients with EGFR-mutated advanced NSCLC. This combination therapy is engineered to provide dual inhibition of EGFR and MET pathways, thereby delivering enhanced anti-tumor activity while simultaneously minimizing exposure to traditional chemotherapy side effects. This approval signifies an increasing trend within the lung cancer market towards personalized, targeted treatment regimens, which ultimately improve patient outcomes and experience by reducing reliance on conventional chemotherapy.
Lung Cancer Drugs Market Company Landscape And Competitive Strategy
Major companies operating in the lung cancer drugs market are Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC
View The Full Lung Cancer Drugs Market Report:
Lung Cancer Drugs Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the lung cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model